Memantine Hydrochloride Crescent Pharma

Memantine Hydrochloride, the active ingredient in Memantine Hydrochloride Crescent Pharma, is an NMDA receptor antagonist presented as an oral tablet for oral use. It treats Alzheimer’s disease in adults by helping to preserve cognitive function and daily activities.

GNH USA supplies Memantine Hydrochloride Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is a NMDA‑receptor antagonist used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

Alzheimer's disease (moderate to severe): helps maintain cognitive function and daily living abilities. Alzheimer's disease (mild to moderate): may support early symptom control and delay functional decline.

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Insomnia

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Severe allergic reaction (rash, swelling, anaphylaxis) - Hallucinations or psychosis - Suicidal thoughts or behavior - Liver function abnormalities

When prescribing Memantine Hydrochloride, clinicians should consider several safety factors. - Renal impairment: adjust dose and monitor renal function. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: evaluate risk before initiating therapy. - Concurrent use with other NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy: risk unknown; use only if clearly needed. - Store at below 25°C: keep in the original pack, protect from moisture.

Memantine Hydrochloride may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects. - Ketamine: combined CNS depression and dissociation risk. - Moxifloxacin: heightened seizure potential.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhanced hypotensive effect. - Diuretics: may affect electrolyte balance and renal clearance. - Other CNS depressants (e.g., benzodiazepines): monitor for increased sedation.